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Abstract
Purpose To report a case of recurrent ocular inflammation
after optimal therapy of bilateral syphilitic panuveitis
responding to oral celecoxib.
Methods A case report was conducted.
Results A 76-year-old man presented with painful blurry
vision in both eyes. Ocular examination disclosed bilateral
panuveitis. Serological testing confirmed blood and cerebro-
spinal fluid syphilitic involvement. After 2 weeks of intrave-
nous penicillin therapy, recurrent episodic sclerouveitis was
observed.
Conclusion Ocular inflammation after healing of infectious
uveitis is a rare ophthalmic sequela. In an immunocompe-
tent patient, either re-infection or immune uveitis should be
evoked. Non-steroidal therapeutic options, as celecoxib,
could be a good option of treatment in such immune cases.
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Introduction
Syphilis is experiencing an extreme increase of its
incidence in Europe and the USA since the early 2000s
[1]. Although penicillin is considered an excellent effective
therapy against Treponema pallidum, patients HIV positive
with cerebrospinal fluid involvement can fail treatment [2].
In immunocompetent patients, either immune uveitis or
syphilitic re-infection should be evoked if ocular inflam-
mation is observed after optimal therapy.
We report a syphilitic panuveitis presenting recurrent
ocular inflammation after correct treatment with penicillin,
treated with celecoxib, a nonsteroidal anti-inflammatory
drug selective for cyclooxygenase-2.
Case description
A 76-year-old immunocompetent man presented with
discomfort and blurry vision in both eyes for the last
week. He reported bilateral recurrent episodic conjuncti-
val injection for the last year. Best-corrected visual acuity
(BCVA) was 20/25 OD and 20/200 OS. Slit-lamp
examination revealed 1+ cells and rare flare with fine
keratic precipitates and 4+ cells with hypopyon in the
right and left eye, respectively (Fig. 1a and b). Dilated
fundus exam showed dense vitritis and hyperemic optic
nerve with blurred margins in both eyes. Fluorescein
angiography disclosed bilateral disk leakage (Fig. 1c and
d). Extensive workup undertaken revealed a serum T.
pallidum RPR titer of 1:256 and positive TPHA. Lumbar
punction confirmed central nervous system involvement.
No HIV infection was associated. The patient completed a
2-week cycle of intravenous penicillin G and topical
steroids, experiencing a complete resolution of panuveitis
and BCVA of 20/20 in both eyes. After 3 weeks of the end
of treatment, the patient presented up to three anterior
sclerouveitis episodes, responding to topical steroids. A
re-infection of Treponema was microbiologically and
clinically ruled out, so an immune ocular response was
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evoked, starting with celecoxib 200 mg a day, with
progressive improvement and no recurrences observed
for 1 year of follow-up.
Discussion
Interaction of T. pallidum with the host's immune system
stimulates humoral and cellular immunity. T. pallidum
produces lipoproteins on the outer membrane that interact
with lipopolysaccharide-binding proteins, inducing the
expression of inflammatory mediators via CD14 and toll-
like receptor 2 recognition. Treponemes also possess
glycolipids linked to the outer membrane that resemble
bacterial lipopolysaccharide. These glycolipids induce
cellular activation by releasing pro-inflammatory cytokines,
mainly tumoral necrosis factor alpha [3], even after
successful penicillin treatment.
Recurrent ocular inflammation after infectious uveitis
treatment is a rare ocular sequela. In the immunocompetent
host, such as our patient, it can occur due to a syphilitic re-
infection or to an immune process, which may be caused by
antigenically inert treponema cell surface. To our knowledge,
this is the first report of an immune response after optimal
treatment of ocular syphilis at an immunocompetent host.
NSAIDs have an anti-chemotactic activity and modulate
both humoral and cellular pathways. Systemic NSAIDs
such celecoxib are known to control ocular inflammatory
processes such chronic iridocyclitis or recurrent acute
anterior uveitis [4, 5], being suitable and sparing-steroids
option of therapy in these cases.
In conclusion, the outer treponema surface may play a
role in immune responses observed after syphilis treatment.
We present the first case reported in literature of immune
sclerouveitis after neurosyphilis treatment treated success-
fully with celecoxib.
Fig. 1 a Slit-lamp photograph
demonstrating anterior uveitis
with hypopyon in the left eye. b
Slit-lamp photograph showing a
cellular reaction and keratic
precipitates in the right eye. c
and d Fundus fluorescein an-
giogram revealing vitritis and
leakage in both optic nerves. e
and f Bilateral episodic anterior
sclerouveitis after penicillin
treatment
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